179 related articles for article (PubMed ID: 38099309)
1. The Aurora kinase inhibitor AT9283 inhibits Burkitt lymphoma growth by regulating Warburg effect.
Jiang K; Bai L; Wang C; Xiao X; Cheng Z; Peng H; Liu S
PeerJ; 2023; 11():e16581. PubMed ID: 38099309
[TBL] [Abstract][Full Text] [Related]
2. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
3. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
[TBL] [Abstract][Full Text] [Related]
4. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
5. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
[TBL] [Abstract][Full Text] [Related]
6. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
[TBL] [Abstract][Full Text] [Related]
7. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.
Cozzi M; Giorgi F; Marcelli E; Pentimalli F; Forte IM; Schenone S; D'Urso V; De Falco G; Botta M; Giordano A; Indovina P
Cell Cycle; 2012 Mar; 11(5):1029-39. PubMed ID: 22333592
[TBL] [Abstract][Full Text] [Related]
9. [Effects of Emodin Derivative on Cell Cycle, Apoptosis and NF-κB Pathway in Burkitt Lymphoma Cells].
Cheng DF; Yang BX; Liu WJ; Qiu CX; Liao JR; Qiu YY; Liu TB; Hu JD; Wang WF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):474-488. PubMed ID: 33812418
[TBL] [Abstract][Full Text] [Related]
10. The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.
Tong X; Zhang X; Fan J; Tong Y; Li S; Jin J; Yao H
Cancer Biol Ther; 2013 Apr; 14(4):370-7. PubMed ID: 23360784
[TBL] [Abstract][Full Text] [Related]
11. Different Mechanisms of Regulation of the Warburg Effect in Lymphoblastoid and Burkitt Lymphoma Cells.
Mushtaq M; Darekar S; Klein G; Kashuba E
PLoS One; 2015; 10(8):e0136142. PubMed ID: 26312753
[TBL] [Abstract][Full Text] [Related]
12. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
Jayanthan A; Cooper TM; Hoeksema KA; Lotfi S; Woldum E; Lewis VA; Narendran A
Leuk Lymphoma; 2013 Jul; 54(7):1505-16. PubMed ID: 23176524
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of long non‑coding RNA ANRIL inhibits the proliferation and promotes the apoptosis of Burkitt lymphoma cells through the TGF‑β1 signaling pathway.
Mao S; Jin J; Li Z; Yang W
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33325535
[TBL] [Abstract][Full Text] [Related]
14. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Foran J; Ravandi F; Wierda W; Garcia-Manero G; Verstovsek S; Kadia T; Burger J; Yule M; Langford G; Lyons J; Ayrton J; Lock V; Borthakur G; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):223-30. PubMed ID: 24355079
[TBL] [Abstract][Full Text] [Related]
16. [Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].
Tu DY; Zhang M; Yin WJ; Xu LY; Sang W; Li ZY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):930-938. PubMed ID: 35045655
[No Abstract] [Full Text] [Related]
17. Suppressed "Warburg Effect" in Nasopharyngeal Carcinoma Via the Inhibition of Pyruvate Kinase Type M2-Mediated Energy Generation Pathway.
Zhao P; Zhou M; Chen R; Su R
Technol Cancer Res Treat; 2020; 19():1533033820945804. PubMed ID: 32815467
[TBL] [Abstract][Full Text] [Related]
18. Pan-Aurora Kinase Inhibitor Danusertib Induces Apoptosis of Epstein-Barr Virus-transformed B-Cells Through Caspase and Endoplasmic Reticulum Stress Signaling.
Kim JS; Hur DY
Anticancer Res; 2022 Nov; 42(11):5265-5274. PubMed ID: 36288888
[TBL] [Abstract][Full Text] [Related]
19. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
20. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Broecker-Preuss M; Becher-Boveleth N; Bockisch A; Dührsen U; Müller S
J Transl Med; 2017 Jul; 15(1):158. PubMed ID: 28724379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]